Viral respiratory tract infections in the immunocompetent

Current Opinion in Infectious Diseases

Volumn 9, Issue 2, 1996, Pages 85-88

  Monto, Arnold S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; INFLUENZA VACCINE;

HANTAVIRUS PULMONARY SYNDROME; HIGH RISK PATIENT; INFECTION RISK; INFLUENZA; MORBIDITY; MORTALITY; PARAINFLUENZA VIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RISK FACTOR; SHORT SURVEY;

EID: 0029988496     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199604000-00008     Document Type: Short Survey

References (30)

1. Monto AS: Influenza vaccines for the elderly [Editorial Review]. New Engl J Med 1994, 331:807-808. A brief editorial review of the evaluations of influenza vaccination in the elderly and comments on future prospects for new interventions.
2. Nichol KL, Margolis KL, Wourenma J, Von Sternberg T: The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. New Engl J Med 1994, 331:778-784. The effectiveness of influenza vaccine is found to be significant in the elderly in preventing hospitalization and death. It is also cost saving to the comprehensive health plan.
3. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, Rhodes PH: Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994, 121:947-952. Confirmation using case-control design of the effectiveness and cost savings of influenza vaccine for the elderly.
4. Bennett NM, Lewis B, Doniger AS, Bell K, Kouides R, Laforce FM, Barker W: A coordinated, communitywide program in Monroe country, New York, to increase influenza immunization rates in the elderly. Arch Intern Med 1994, 154:1741-1745.
5. Karuza J, Calkins E, Feather J, Hershey CO, Katz L, Majeroni B: Enhancing physician adoption of practice guidelines. Dissemination of influenza vaccination guideline using a small-group consensus process. Arch Intern Med 1995, 155:625-632.
6. Nicholson KG, Snacken R, Palache AM: Influenza immunization policies in Europe and the United States. Vaccine 1995, 13:365-369.
7. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA: The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272:1661-1665. Individuals 60 years of age and older were randomly assigned to receive inactivated influenza vaccine or placebo. Laboratory-confirmed influenza illnesses were reduced by 50% in the vaccinated, even though the circulating strain had drifted from that in the vaccine.
8. Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M: Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 1994, 272:1122-1126.
9. Arden N, Monto AS, Ohmit SE: Vaccine use and the risk of outbreaks in a sample of nursing homes during an influenza epidemic. Am J Public Health 1995, 85:399-401. Outbreaks of influenza still occur in well vaccinated nursing homes. They are less likely in smaller nursing homes and those with higher vaccination rates.
10. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N: Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Arch Intern Med 1995; 155:533-537.
11. Hayden FG, Rollins BS, Madren LK: Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994, 25:123-131.
12. Wang EEL, Law BJ, Stephens D, Boucher F, Couillard M, Dobson S, Thomas E, Langley J, Lee S, Mcdonald J, et al.: Pediatric investigators collaborative network on infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995, 126:212-219.
13. Hornstrup MK, Trommer B, Siboni K, Nielsen B, Kamper J: Nosocomial respiratory syncytial virus infections in a paediatric department. J Hosp Infect 1994, 26:173-179.
14. Siber GR, Leombruno D, Leszczynski J, McIver J, Bodkin D, Gonin R: Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1994, 169:1368-1373.
15. Groothuis JR, Simoes EA, Hemming VG, (Respiratory Syncytial Virus Immune Globulin Study Group): Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 1995, 95:463-467. An analysis of a subset of cases from a randomized trial of RSV immune globulin against placebo. Data suggest that the use of the preparation in high-risk preterm children will reduce severe outcomes.
16. Connors M, Crowe JE Jr, Firestone CY, Murphy BR, Collins PL: A cold- passaged, attenuated strain of human respiratory syncytial virus contains mutation in the F and L genes. Virology 1995, 208:478-484.
17. Hsu KH, Crowe JE Jr, Lubeck MD, Davis AR, Hung PP, Chanock RM, Murphy BR: Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus. Vaccine 1995, 13:509-515.
18. Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefson S, Steinhoff MC, Wilson MH, Harris DO, et al.: A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995, 171:1107-1114.
19. Ray R, Meyer K, Newman FK, Belshe RB: Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain. J Virol 1995, 69:1959-1963.
20. Calhoun WJ, Dick EC, Schwartz LB, Busse WW: A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994, 94:2200-2208. Infection and provocation produces enhanced histamme response and recruitment of eosinophils. Results suggest a mechanism which leads to bronchial inflammation.
21. Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST: Immunohistochemical analysis of nasal biopsies during rhinovirus experimental colds. Am J Respir Crit Care Med 1994, 150:1130-1136.
22. Sigurs N, Bjarnason R, Sigurbergsson F, Kejellman B, Bjorksten B: Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995, 95:500-505. A prospective study of infants after severe RSV bronchiolitis. The children are more likely than companions to develop asthma and sensitization in the next 2 years.
23. Hayden FG, Hipskind GJ, Woerner DH, Eisen GF, Janssens M, Janssen PA, Andries K: Intranasal pirodavir (R77, 975) treatment of rhinovirus colds. Antimicrob Agents Chemother 1995, 39:290-294.
24. Shefer AM, Tappero JW, Bresee JS, Peters CJ, Ascher MS, Zaki SR, Jackson RJ, Werner SB, Rollin PE, Ksiazek TG, et al.: Hantavirus pulmonary syndrome in California: report of two cases and investigation. Clin Infect Dis 1994, 19:1105-1109.
25. Turell MJ, Korch GW, Rossi CA, Sesline D, Enge BA, Dondero DV, Jay M, Ludwig GV, Li D, Schmaljohn CS, et al.: Short report: prevalence of hantavirus infection in rodents associated with two fatal human infections in California. Am J Trop Med Hyg 1995, 52:180-182.
26. Morzunov SP, Feldmann H, Spiropoulou CF, Semenova VA, Rollin PE, Ksiazek TG, Peters CJ, Nichol ST: A newly recognized virus associated with a fatal case of hantavirus pulmonary syndrome in Louisiana. J Virol 1995, 69:1980-1983.
27. Elliott LH, Ksiazek TG, Rollin PE, Spiropoulou CF, Morzunov S, Monroe M, Goldsmith CS, Humphrey CD, Zaki SR, Krebs JW, et al.: Isolation of the causative agent of hantavirus pulmonary syndrome. Am J Trop Med Hyg 1994, 51:102-108. Passage of the causative virus is reported from deer mice to the Vero Eb cell line. The tentative name of the virus, Muerto Canyon, has been submitted to the American Committee on Arthropod-borne Viruses.
28. Childs JE, Krebs JW, Ksiazek TG, Maupin GO, Gage KL, Rollin PE, Zeitz PS, Sansky J, Enscore RE, Butler JC, et al.: A household-based, case- control study of environmental factors associated with hantavirus pulmonary syndrome in the southwestern United States. Am J Trop Med Hyg 1995, 52:393-397.
29. Zeitz PS, Butler JC, Cheek JE, Samuel MC, Childs JE, Shands LA, Turner RE, Voorhees RE, Sarisky J, Rollin PE, et al.: A case-control study of hantavirus pulmonary syndrome during an outbreak in the southwestern United States. J Infect Dis 1995, 171:864-870. A case-control study of HPS which identified the presence of small rodents in the household as the most important risk factor.
30. Monto AS, Ohmit SE, Margulies JR, Talsma A: Medical practice-based influenza surveillance: viral prevalence and assessment of morbidity. J Epidemiol 1995, 141:502-506.